US2012064119A1PendingUtilityA1

Neisserial vaccine compositions comprising a combination of antigens

Assignee: BERTHET FRANCOIS-XAVIER JACQUESPriority: Aug 2, 2002Filed: Nov 17, 2011Published: Mar 15, 2012
Est. expiryAug 2, 2022(expired)· nominal 20-yr term from priority
A61P 37/02A61P 37/04A61P 43/00A61P 37/00A61P 31/00A61P 31/04A61K 2039/55516A61K 39/1045A61K 39/102A61K 2039/521A61K 2039/55577A61K 39/095A61K 2039/55572A61K 2039/55505C07K 14/22A61K 2039/70A61P 11/00C12N 15/00A61K 39/02Y02A50/30
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response.

Claims

exact text as granted — not AI-modified
1 . A vaccine composition comprising immunogenic levels of at least one Neisserial autotransporter protein antigen, at least one Neisserial Fe acquisition protein antigen, and at least one different Neisserial outer membrane protein antigen, wherein the at least one Neisserial autotransporter protein antigen is NadA or Hsf, and the at least one Neisserial Fe acquisition protein antigen is transferrin binding protein related protein (Tbprp) or TbpA, said composition further comprising an outer membrane vesicle preparation comprising an LPS immunotype L3. 
     
     
         2 . The vaccine composition of  claim 1 , wherein at least one of the Neisserial protein antigens is an antigen derived from  Neisseria meningitidis.    
     
     
         3 . The vaccine composition of  claim 1 , wherein all of the Neisserial protein antigens are derived from  N. meningitidis.    
     
     
         4 . The vaccine composition of  claim 1  further comprising one or more bacterial capsular polysaccharides or oligosaccharides. 
     
     
         5 . The vaccine composition of  claim 4 , wherein the capsular polysaccharides or oligosaccharides are derived from bacteria selected from the group consisting of:  Neisseria meningitidis  serogroup A, C, Y and W-135. 
     
     
         6 . The vaccine composition of  claim 1  further comprising an adjuvant. 
     
     
         7 . The vaccine composition of  claim 6 , wherein the adjuvant comprises an aluminum salt. 
     
     
         8 . The vaccine composition of  claim 6 , wherein the adjuvant comprises aluminum hydroxide gel. 
     
     
         9 . The vaccine composition of  claim 1 , wherein the outer membrane protein antigen is GNA1870. 
     
     
         10 . The vaccine composition of  claim 1 , wherein the Neisseral autotransporter protein antigen is NadA. 
     
     
         11 . The vaccine composition of  claim 1 , wherein the Neisseral Fe acquisition protein antigen is transferrin binding protein related protein.

Join the waitlist — get patent alerts

Track US2012064119A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.